Details of the Drug Combinations

General Information of This Drug (ID: DMRF9YK)

• Drug Name: Empagliflozin (DMRF9YK)
• Synonyms: 864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Indication

Type-1 diabetes; ICD 11: 5A10; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dapagliflozin + Empagliflozin	DC3Y735	Dapagliflozin	Diabetes Mellitus, Type 2	[2]
Empagliflozin + Gemigliptin	DC7HT3V	Gemigliptin	Type 2 Diabetes Mellitus	[3]
Imiglitazar + Empagliflozin	DC6OTX1	Imiglitazar	T2DM	[4]
Liraglutide + Empagliflozin	DCHEELX	Liraglutide	Diabetes Mellitus, Type 2	[5]
Lobeglitazone + Empagliflozin	DCIATLI	Lobeglitazone	Diabetes Mellitus, Type II	[6]
Valsartan + Empagliflozin	DC650YQ	Valsartan	Diabetic Nephropathies	[7]
Dapagliflozin + Empagliflozin	DC63T70	Dapagliflozin	Acute Decompensated Heart Failure	[8]
Rosuvastatin + Empagliflozin	DC3BTJ5	Rosuvastatin	Dyslipidemia Associated With Type II Diabetes Mellitus	[9]
Rosuvastatin + Empagliflozin	DCYI9W8	Rosuvastatin	Type 2 Diabetes Mellitus	[10]
2,3-dihydroxypropanal + Empagliflozin	DCRUE77	2,3-dihydroxypropanal	Obesity, Visceral	[11]
Empagliflozin + Losartan	DCATMLS	Losartan	Diabetes Mellitus, Type 2	[12]
Linagliptin + Empagliflozin	DC85EFN	Linagliptin	Type 2 Diabetes Mellitus	[13]
Semaglutide + Empagliflozin	DCITDAS	Semaglutide	Type 2 Diabetes With Renal Manifestations	[14]

2 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Metformin + Empagliflozin	DCBEIHD	Metformin	Type-2 diabetes	[15]
Linagliptin + Empagliflozin	DCK3417	Linagliptin	Type-2 diabetes	[16]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4754).
• [2] ClinicalTrials.gov (NCT03492580) A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
• [3] ClinicalTrials.gov (NCT03565458) Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
• [4] ClinicalTrials.gov (NCT05681273) Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
• [5] ClinicalTrials.gov (NCT03993132) A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
• [6] ClinicalTrials.gov (NCT02854748) Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
• [7] ClinicalTrials.gov (NCT05638880) Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
• [8] ClinicalTrials.gov (NCT05776043) Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
• [9] ClinicalTrials.gov (NCT04602754) Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
• [10] ClinicalTrials.gov (NCT04603508) Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
• [11] ClinicalTrials.gov (NCT02833415) Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
• [12] ClinicalTrials.gov (NCT04238702) Renohemodynamic Effects of Combined empagliflOzin and LosARtan
• [13] ClinicalTrials.gov (NCT02401880) Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
• [14] ClinicalTrials.gov (NCT04061200) Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030467)
• [16] ClinicalTrials.gov (NCT01734785) Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes. U.S. National Institutes of Health.